Effects of somatostatin on insulin and glucagon in patients with insulinoma

Franco Fallucca, C. Mirabella, G. Tamburrano, S. Gambardella, G. Aufieri, F. Barbetti, D. Andreani

Research output: Contribution to journalArticlepeer-review


Effects of somatostatin on fasting and arginine- or tolbutamide-stimulated insulin release were studied in four patients with insulinoma. Somatostatin (bolus or bolus + infusion) reduced fasting insulin values in all patients; insulin response to tolbutamide was partially reduced in two patients; somatostatin bolus impaired the insulin response to arginine. Fasting glucagon levels and glucagon response to arginine were also reduced by somatostatin. These results indicate the potential usefulness of somatostatin in the diagnosis of insulinoma even if its effect on insulin is only partial.

Original languageEnglish
Pages (from-to)257-260
Number of pages4
JournalJournal of Endocrinological Investigation
Issue number3
Publication statusPublished - 1979


  • arginine
  • Glucagon
  • insulin
  • insulinoma
  • somatostatin
  • tolbutamide

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Effects of somatostatin on insulin and glucagon in patients with insulinoma'. Together they form a unique fingerprint.

Cite this